SCNI Profile
Scinai Immunotherapeutics Ltd., headquartered in Jerusalem, Israel, is a development-stage biopharmaceutical company dedicated to advancing the treatment and prevention of infectious and autoimmune diseases, among other illnesses. The company specializes in the development, manufacturing, and commercialization of innovative therapeutic products, with a focus on harnessing cutting-edge biotechnology to address unmet medical needs.
Scinai Immunotherapeutics is actively involved in the development of nanosized antibody (NanoAb) therapies through its licensing and collaboration agreements with the Max Planck Society and University Medical Center Göttingen. These partnerships are focused on the development and commercialization of NanoAb technologies for COVID-19 and other disease indications. NanoAb therapies represent a novel approach to treatment, offering potential advantages in terms of efficacy and targeted action against specific pathogens and disease processes.
In addition to its COVID-19-related initiatives, Scinai Immunotherapeutics is exploring the application of NanoAb technology for a range of other disease indications. This broad research scope underscores the company's commitment to leveraging its innovative platform to address diverse therapeutic challenges and improve patient outcomes across multiple disease areas.
Originally founded as BiondVax Pharmaceuticals Ltd. in 2003, the company rebranded to Scinai Immunotherapeutics Ltd. in September 2023 to better reflect its evolving focus and strategic direction. With its extensive research collaborations and a robust pipeline of therapeutic products, Scinai Immunotherapeutics continues to make strides in the biopharmaceutical industry, aiming to advance the frontier of immunotherapy and provide effective solutions for serious health conditions.
|
